<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004507</url>
  </required_header>
  <id_info>
    <org_study_id>NYX-SNV</org_study_id>
    <nct_id>NCT04004507</nct_id>
  </id_info>
  <brief_title>Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances</brief_title>
  <acronym>SNV</acronym>
  <official_title>Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocuphire Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocuphire Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:

        -  To assess the effect of ophthalmic phentolamine mesylate in mesopic conditions on the
           four endpoints:

             1. Contrast sensitivity

             2. Low contrast visual acuity

             3. Wavefront aberrometry

             4. Subjective questionnaire

        -  To assess the safety of ophthalmic phentolamine mesylate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-masked, placebo-controlled, single-dose Phase 2 study in 24 patients experiencing
      severe night vision difficulties to evaluate ocular and systemic safety and efficacy
      following administration of one drop of phentolamine mesylate 1.0% QD in each eye for 1 day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>1 day</time_frame>
    <description>Average change in monocular contrast sensitivity scores under mesopic conditions at each of five spatial frequencies with and without glare</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>1 day</time_frame>
    <description>Average number of letters of improvement in the following parameters:
Distance high-contrast visual acuity under mesopic conditions (monocular, measured at 4 meters)
Distance high-contrast visual acuity under photopic conditions (monocular, measured at 4 meters)
Distance low-contrast visual acuity under mesopic conditions (monocular, measured at 4 meters)
Distance low-contrast visual acuity under photopic conditions (monocular, measured at 4 meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wavefront Aberrometry</measure>
    <time_frame>1 day</time_frame>
    <description>Wavefront aberrometry under mesopic conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Reported Vision Quality</measure>
    <time_frame>1 day</time_frame>
    <description>Subjective patient evaluations of vision quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupil Diameter</measure>
    <time_frame>1 day</time_frame>
    <description>Average change in pupil diameter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Decrease in Night Vision</condition>
  <condition>Disturbance; Vision, Loss</condition>
  <arm_group>
    <arm_group_label>Phentolamine Mesylate Ophthalmic Solution 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye (QD) for one day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phentolamine Mesylate Ophthalmic Solution Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 drop in each eye (QD) for one day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentolamine Mesylate Ophthalmic Solution 1%</intervention_name>
    <description>Topical Sterile Ophthalmic Solution</description>
    <arm_group_label>Phentolamine Mesylate Ophthalmic Solution 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)</intervention_name>
    <description>Topical Sterile Ophthalmic Solution</description>
    <arm_group_label>Phentolamine Mesylate Ophthalmic Solution Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients â‰¥ 18 years of age

          2. Currently experiencing severe night vision difficulty as reported subjectively

          3. At least two patches below the normal range at any two frequencies in Contrast
             Sensitivity done under mesopic conditions with glare

          4. Improvement in low contrast visual acuity (LCVA) in dim light during illumination of
             contralateral eye

          5. Good general health

          6. Written informed consent to participate in this trial

          7. Ability to comply with all protocol mandated procedures and to attend all scheduled
             office visits

        Exclusion Criteria:

          1. Patients with untreated cataracts grades 1-4

          2. Patients who wear contact lenses

          3. Less than 5 weeks post-refractive surgery (LASIK or PRK)

          4. Less than 5 weeks post intraocular lens insertion

          5. Low blood pressure (systolic &lt;120 mm Hg or diastolic &lt;80 mm Hg)

          6. A history of heart rate abnormalities

          7. Administration of any investigational drug within 30 days of study initiation

          8. Use of any eye drops with a pharmacologic effect on the pupil within 7 days of Visit 1

          9. Use of any systemic alpha adrenergic antagonists (Appendix 1)

         10. Known local or systemic hypersensitivity to adrenergic antagonists

         11. For women of childbearing potential: currently pregnant or lactating, or unwilling to
             use birth control during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marguerite McDonald, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Consultants of Long Island, NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island, NY</name>
      <address>
        <city>Lynbrook</city>
        <state>New York</state>
        <zip>11563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Night Vision Disturbances</keyword>
  <keyword>NVD</keyword>
  <keyword>Glare</keyword>
  <keyword>Halos</keyword>
  <keyword>Starbursts</keyword>
  <keyword>Nyxol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phentolamine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

